Letter to the Editor

Abstract

Get full access to this article

View all access options for this article.

References

Ghalie RG , Mauch E , Edan G , Hartung HP , Gonsette RE , Eisenmann S et al. A study of therapy-related acute leukemia after mitoxantrone therapy for multiple sclerosis . Mult Scler 2002; 8: in press.

Felix CA. Secondary leukemias induced by topoisomerase-targeted drugs . Biochem Biophys Acta 1998; 1400: 233-255 .

Pedersen-Bjergaard J , Philip P. Two different classes of therapy-related and de novo acute myeloid leukemia ? Cancer Genet Cytogenet 1991; 55: 119-124 .

Vicari AM , Ciceri F , Folli F , Lanzi R , Colombo B , Comi G et al. Acute promyelocytic leukemia following mitoxantrone as single agent for treatment of multiple sclerosis . Leukemia 1998; 12: 441-442 .

Edan G and the French Mitoxantrone Safety Study Group . Safety profile of mitoxantrone in a cohort of 800 multiple sclerosis patients . Mult Scler 2001; 7: S14-S14 .

Linassier C , Barin C , Calais G , Letortorec S , Brémon JL , Delain M et al. Early secondary acute myelogenous leukemia in breast cancer patients after treatment with mitoxantrone, cyclophosphamide, fluoruracil and radiation therapy . Ann Oncol 2000; 11: 1289-1294 .

Quesenel B , Kantajian H , Bjergaard JP , Brault P , Estey E , Lai JL et al. Therapy related acute myeloid leukemia with t(8;21), inv (16), and t(8;16): a report on 25 cases and review of the literature . J Clin Oncol 1993; 11: 2370-2379 .